ASCO 2021: Updates in CAR-T

ASCO 2021: Updates in CAR-T

Anti-CLL1 CAR T Cells Produce Responses in Pediatric Acute Myeloid Leukemia

In a phase 1/2 trial, 8 of 11 patients with relapsed or refractory AML achieved a complete response with CAR T-cell therapy targeting C-type lectin-like molecule-1.

Cancer Therapy Advisor
CAR-T Cell Therapy Shows Promise in Pretreated Patients With Multiple Myeloma

Ciltacabtagene autoleucel, a BCMA-targeting therapy, appears to show promising activity among patients with previously treated MM, per research presented at the 2021 ASCO Annual Meeting.

Hematology Advisor
OriginCell Therapeutics Presents Positive Results of GPC3 CAR-T in HCC Trial at the 2021 ASCO Annual Meeting

SHANGHAI, June 6, 2021 /PRNewswire/ -- On June 4, 2021 (EST), OriginCell Therapeutics (Shanghai) Co., Ltd. ("OriginCell"), together with Lishui Central Hospital affiliated to Zhejiang University and Shanghai Changzheng Hospital, presented the updated data from the on-going trial of Ori-CAR-001, a GPC3 CAR-T cell therapy for the treatment of relapsed/refractory hepatocellular carcinoma (HCC), at the 2021 annual meeting of American Society of Clinical Oncology. 


Tecartus Demonstrates High Response Rate in Adults With R/R B-cell ALL Earning Priority Review Designation

Results of the primary analysis of Tecartus (brexucabtagene autoleucel) in adults with relapsed/refractory B-cell precursor ALL were simultaneously published in The Lancet and presented at

Legend Biotech Announces New and Updated Data for Investigational BCMA CAR-T Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed or Refractory Multiple Myeloma at 2021 ASCO and EHA Meetings

Legend Biotech announced today that new and updated results for ciltacabtagene autoleucel (cilta-cel), an investigational BCMA-directed CAR-T therapy for R/R MM, will be featured at ASCO 2021 and a

CBMG Holdings Announces Data from 2 CAR-T Clinical Studies Selected for Podium Presentations at the ASCO Annual Meeting

CBMG Holdings today announced the publication of 2 abstracts of CAR-T therapies for liquid tumors published in conjunction with the 2021 ASCO Annual Meeting.

ASCO 2021: Off-the-Shelf Cell Therapy Inches Towards Reality

According to Allogene, lymphoma data being presented at ASCO show that its anti-CD19 CAR-T therapy, ALLO-501, is on a par with autologous rivals.


source list reference

rgb(171, 222, 222)
200, 66, 245
rgb(195, 2, 230)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(242, 0, 137)
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb(156, 242, 7)
rgb(224, 4, 129)
rgb(80, 147, 199)
rgb(5, 235, 235)
rgb(235, 190, 9)
rgb(209, 227, 11)
200, 66, 245
rgb(217, 7, 192)
rgb(2, 230, 230)